A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

NCT05039736 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants accrued

Conditions

Hepatocellular Carcinoma
Liver Cancer

Interventions

DRUG: Cabozantinib
DRUG: Nivolumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]